The phosphatidylinositol 3-kinase/Akt pathway regulates the HCCR-1 oncogene expression

Gene

Volumn 384, Issue 1-2, 2006, Pages 18-26

  Cho, Goang Won ^a   Shin, Seung Min ^a   Namkoong, Hong ^a   Kim, Hyun Kee ^a   Ha, Seon Ah ^a   Hur, Soo Young ^a   Kim, Tae Eung ^a   Chai, Young Gyu ^b   Kim, Jin Woo ^a  

^a The Catholic University of Korea   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

Homeodomain; Human cancer; K562; LY 294002; Promoter

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL ACTIVATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EMBRYO DEVELOPMENT; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; WILD TYPE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 5' FLANKING REGION; ANIMALS; BASE SEQUENCE; CELL LINE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NIH 3T3 CELLS; ONCOGENE PROTEINS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 33750936552     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gene.2006.07.006     Document Type: Article

References (28)

1. Balmain A., Gray J., and Ponder B. The genetics and genomics of cancer. Nat. Genet. 33 (2003) 238-244
2. Brunet A., Datta S.R., and Greenberg M.E. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol. 11 (2001) 297-305
3. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
4. Cartharius K., et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21 (2005) 2933-2942
5. Choi Y., et al. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 21 (2002) 5289-5300
6. DeGraffenried L.A., Fulcher L., Friedrichs W.E., Grunwald V., Ray R.B., and Hidalgo M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3kinase/Akt pathway. Ann. Oncol. 15 (2004) 1510-1516
7. Franke T.F., et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81 (1995) 727-736
8. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., and Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30 (2004) 193-204
9. Fruman D.A., Meyers R.E., and Cantley L.C. Phosphoinositide kinases. Annu. Rev. Biochem. 67 (1998) 481-507
10. Geerts D., Revet I., Jorritsma G., Schilderink N., and Versteeg R. MEIS homeobox genes in neuroblastoma. Cancer Lett. (2005) 1-8
11. Jung S.S., et al. The HCCR oncoprotein as a biomarker for human breast cancer. Clin. Cancer Res. 11 (2005) 7700-7708
12. Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., and Waterfield M.D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17 (2001) 615-675
13. Kaufmann W.K., and Kaufman D.G. Cell cycle control, DNA repair and initiation of carcinogenesis. FASEB J. 7 (1993) 1188-1191
14. Ko J., et al. Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization. Oncogene 22 (2003) 4679-4689
15. Ko J., et al. Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice. Oncogene 23 (2004) 1950-1953
16. Lawlor M.A., and Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. J. Cell Sci. 114 (2001) 2903-2910
17. Liu D., Yang X., and Songyang Z. Identification of CISK, a new member of the SGK kinase family that promotes IL-3-dependent survival. Curr. Biol. 10 (2000) 1233-1236
18. Martin G.S. Cell signaling and cancer. Cancer Cells 4 (2003) 167-174
19. Morgensztern D., and McLeod H.L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-Cancer Drugs 16 (2005) 797-803
20. Nishida W., et al. A triad of serum response factor and the GATA and NK families governs the transcription of smooth and cardiac muscle genes. J. Biol. Chem. 277 (2002) 7308-7317
21. Okkenhaug K., and Vanhaesebroeck B. New responsibilities for the PI3K regulatory subunit p85 alpha. Sci. STKE 65 (2001) 1-5
22. Pandolfi P.P. Breast cancer-loss of PTEN predicts resistance to treatment. N. Engl. J. Med. 351 (2004) 2337-2338
23. Popescu N.C. Comprehensive genetic analysis of cancer cells. J. Cell. Mol. Med. 4 (2000) 151-163
24. Sander G., Bawden C.S., Hynd P.I., Nesci A., Rogers G., and Powell B.C. Expression of the homeobox gene, Barx2, in wool follicle development. J. Invest. Dermatol. 115 (2000) 753-756
25. Shayesteh L., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21 (1999) 99-102
26. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev., Cancer 2 (2002) 489-501
27. Vlahos C.J., Matter W.F., Hui K.Y., and Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269 (1994) 5241-5248
28. Vogelstein B., and Kinzler K.W. The Genetic Basis of Human Cancer (2002), McGraw-Hill, New York